Altimmune, Inc.
NASDAQ Global MarketTotal Valuation
Altimmune, Inc. carries a market capitalization of 427.94M, placing it among publicly traded companies globally. Its enterprise value stands at 300.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 427.94M |
| Enterprise Value | 300.94M |
Share Statistics
Altimmune, Inc. currently has 194.47M shares outstanding.
| Shares Outstanding | 194.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12,256.52, and the price-to-book ratio stands at 1.25.
| PE Ratio | N/A |
| PS Ratio | 12,256.52 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | -4.97 |
| P/OCF Ratio | -4.97 |
Enterprise Valuation
| EV / Sales | 9,707.76 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Altimmune, Inc. maintains a current ratio of 26.78, meaning it holds 26.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.60, indicating elevated leverage, while an interest coverage ratio of -28.32 demonstrates limited ability to service its debt obligations.
| Current Ratio | 26.78 |
| Quick Ratio | 26.37 |
| Debt / Equity | 7.60 |
| Debt / EBITDA | -0.36 |
| Interest Coverage | -28.32 |
Financial Efficiency
| Return on Equity (ROE) | -28.87 |
| Return on Assets (ROA) | -25.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Altimmune, Inc.'s stock has declined approximately -45% over the past 52 weeks. The 50-day moving average sits at 3.00, while the 200-day moving average is 3.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45% |
| 50-Day Moving Average | 3.00 |
| 200-Day Moving Average | 3.37 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Altimmune, Inc. generated 31,000.00 in revenue and converted that into -91.76M in net income, yielding earnings per share of -0.73. EBITDA reached -100.13M, while operating income came in at -100.22M.
| Revenue | 31,000.00 |
| Gross Profit | N/A |
| Operating Income | -100.22M |
| Pretax Income | -91.76M |
| Net Income | -91.76M |
| EBITDA | -100.13M |
| EBIT | -100.22M |
| Earnings Per Share (EPS) | -0.73 |
Balance Sheet
Altimmune, Inc. holds 326.28M in cash and equivalents against 36.02M in total debt, resulting in a net debt position of -28.27M. Total book value stands at 474.21M, with working capital of 322.31M providing operational flexibility.
| Cash & Cash Equivalents | 326.28M |
| Total Debt | 36.02M |
| Net Debt | -28.27M |
| Equity (Book Value) | 474.21M |
| Book Value Per Share | 2.44 |
| Working Capital | 322.31M |
Cash Flow
Altimmune, Inc. produced -76.51M in operating cash flow over the past twelve months. After subtracting -54,000.00 in capital expenditures, free cash flow totaled -76.56M - equivalent to -0.61 per share.
| Operating Cash Flow | -76.51M |
| Capital Expenditures | -54,000.00 |
| Free Cash Flow | -76.56M |
| FCF Per Share | -0.61 |
Margins
Altimmune, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -323,306.45 and net profit margin of -296,000.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -323,306.45 |
| Pretax Margin | -296,000.00 |
| Profit Margin | -296,000.00 |
| EBITDA Margin | -322,987.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -69.35 |
| FCF Yield | -20.12 |
Stock Splits
Altimmune, Inc.'s most recent stock split took place on September 14, 2018 with a 30:1 split ratio.
| Last Split Date | 9/14/2018 |
| Split Ratio | 30:1 |
Scores
Altimmune, Inc. posts an Altman Z-Score of 4.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.95 |